Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 7461426, 6 pages
https://doi.org/10.1155/2017/7461426
Research Article

Small Intestinal Bacterial Overgrowth Affects the Responsiveness to Colchicine in Familial Mediterranean Fever

Periodic Fever Research Centre, Department of Internal Medicine, Policlinico Gemelli Foundation, Catholic University of Sacred Heart, Rome, Italy

Correspondence should be addressed to R. Manna; ti.ttacinu@annam.eleaffar

Received 4 May 2017; Revised 29 September 2017; Accepted 24 October 2017; Published 12 December 2017

Academic Editor: Ciriaco A. Piccirillo

Copyright © 2017 E. Verrecchia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Alghamdi, “Familial Mediterranean fever, review of the literature,” Clinical Rheumatology, vol. 36, no. 8, pp. 1707–1713, 2017. View at Publisher · View at Google Scholar
  2. H. J. Lachmann, B. Sengül, T. U. Yavuzşen et al., “Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations,” Rheumatology, vol. 45, no. 6, pp. 746–750, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Ozen, I. Kone-Paut, and A. Gül, “Colchicine resistance and intolerance in familial Mediterranean fever: definition, causes, and alternative treatments,” Seminars in Arthritis and Rheumatism, vol. 47, no. 1, pp. 115–120, 2017. View at Publisher · View at Google Scholar
  4. D. Cattan, “MEFV mutation carriers and diseases other than familial Mediterranean fever: proved and nonproved association; putative biological advantage,” Current Drug Target-Inflammation & Allergy, vol. 4, no. 1, pp. 105–112, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Cerquaglia, M. Diaco, G. Nucera, M. La Regina, M. Montalto, and R. Manna, “Pharmacological and clinical basis of treatment of familial Mediterranean fever (FMF) with colchicine or analogues: an update,” Current Drug Target -Inflammation & Allergy, vol. 4, no. 1, pp. 117–124, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. J. Chae, H. Komarow, J. Cheng et al., “Targeted disruption of pyrin, the FMF protein, causes hightened sensitivity to endotoxin and a defect in macrophage apoptosis,” Molecular Cell, vol. 11, no. 3, pp. 591–604, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Demirtürk, A. M. Ozel, K. Cekem, Y. Yazgan, and M. Gultepe, “Co-existence of Helicobacter pylori infection in patients with familial Mediterranean Fever (FMF) and the effect of Helicobacter pylori on the frequency and severity of FMF attacks,” Digestive and Liver Disease, vol. 37, no. 3, pp. 153–158, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. A. M. Ozel, L. Demirturk, A. Aydogdu et al., “Effect of Helicobacter pylori infection and eradication therapy on interleukin-6 levels in patients with familial Mediterranean fever,” International Journal of Clinical Practice, vol. 62, no. 5, pp. 754–761, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. U. C. Ghoshal, R. Shukla, and U. Ghoshal, “Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy,” Gut Liver, vol. 11, no. 2, pp. 196–208, 2017. View at Publisher · View at Google Scholar
  10. F. R. Ponziani, V. Gerardi, and A. Gasbarrini, “Diagnosis and treatment of small intestinal bacterial overgrowth,” Expert Review of Gastroenterology & Hepatology, vol. 10, no. 2, pp. 215–227, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Balzan, C. de Almeida Quadros, R. de Cleva, B. Zilberstein, and I. Cecconello, “Bacterial translocation: overview of mechanisms and clinical impact,” Journal of Gastroenterology and Hepatology, vol. 22, no. 4, pp. 464–471, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. E. M. Quigley, “Small intestinal bacterial overgrowth: what it is and what it is not,” Current Opinion in Gastroenterology, vol. 30, no. 2, pp. 141–146, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Scarpignato and L. Gatta, “Commentary: towards an effective and safe treatment of small intestine bacterial overgrowth,” Alimentary Pharmacology & Therapeutics, vol. 38, no. 11-12, pp. 1409-1410, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Livneh, P. Langevitz, D. Zemer, N. Zaks, S. Kees, and T. Lidar, “Criteria for the diagnosis of familial Mediterranean fever,” Arthritis & Rheumatism, vol. 40, no. 10, pp. 1879–1885, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Gabrielli, G. D'Angelo, T. Di Rienzo, E. Scarpellini, and V. Ojetti, “Diagnosis of small intestinal bacterial overgrowth in the clinical practice,” European Review for Medical and Pharmacological Sciences, vol. 17, Supplement 2, pp. 30–35, 2013. View at Google Scholar
  16. G. Corazza, M. Sorge, A. Strocchi, and G. Gasbarrini, “Glucose-H2 breath test for small intestine bacterial overgrowth,” Gastroenterology, vol. 98, no. 1, pp. 253-254, 1990. View at Publisher · View at Google Scholar
  17. G. R. Corazza, G. Benati, A. Strocchi, S. Malservisi, and G. Gasbarrini, “The possible role of breath methane measurement in detecting carbohydrate malabsorption,” Journal of Laboratory and Clinical Medicine, vol. 124, no. 5, pp. 695–700, 1994. View at Google Scholar
  18. E. Pras, A. Livneh, J. E. Balow Jr. et al., “Clinical differences between North African and Iraqi Jews with familial Mediterranean fever,” American Journal of Medical Genetics, vol. 75, no. 2, pp. 216–219, 1998. View at Publisher · View at Google Scholar
  19. A. Mor, Y. Shinar, N. Zaks et al., “Evaluation of disease severity in familial Mediterranean fever,” Seminars in Arthritis and Rheumatism, vol. 35, no. 1, pp. 57–64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Husebye, “The pathogenesis of gastrointestinal bacterial overgrowth,” Chemotherapy, vol. 51, no. 1, pp. 1–22, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. E. Ricci Jr., L. A. Chebli, T. C. Ribeiro et al., “Small-intestinal bacterial overgrowth is associated with concurrent intestinal inflammation but not with systemic inflammation in Crohn’s disease patients,” Journal of Clinical Gastroenterology, p. 1, 2017. View at Publisher · View at Google Scholar
  22. E. Ben-Chetrit and H. Ozdogan, “Non-response to colchicine in FMF – definition, causes and suggested solutions,” Clinical and Experimental Rheumatology, vol. 26, Supplement 50, no. 4, pp. S49–S51, 2008. View at Google Scholar
  23. M. Lidar, J. M. Scherrmann, Y. Shinar et al., “Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic and socioeconomic characterization,” Seminars in Arthritis and Rheumatism, vol. 33, no. 4, pp. 273–282, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Fasano, F. Bove, M. Gabrielli et al., “Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth,” Clinical Neuropharmacology, vol. 37, no. 4, pp. 91–95, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. J. J. Chae, G. Wood, S. L. Masters, K. Richard, B. J. Smith, and D. L. Kastner, “The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production,” Proceedings of the National Academy of Sciences, vol. 103, no. 26, pp. 9982–9987, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. T. H. Morris, S. H. Sorensen, J. Turkington, and R. M. Batt, “Diarrhoea and increased intestinal permeability in laboratory beagles associated with proximal small intestinal bacterial overgrowth,” Laboratory Animals, vol. 28, no. 4, pp. 313–319, 1994. View at Publisher · View at Google Scholar · View at Scopus